SGLT-2 inhibitors can improve CHF symptoms and reduce CHF-related mortality risk. The exact mechanism of how these drugs do ...

may actually have been treating early-stage CHF. Cessation of such therapy, followed by substitution therapy with doxazosin, may have then allowed heart failure symptoms to become manifest.